Oruka Therapeutics
MA - WalthamBiotechnology
Focus: Oruka Therapeutics is a clinical-stage biotech focused on biologic therapies for dermatological diseases, headquartered in Waltham, MA. The company is advancing a pipeline centered on plaque psoriasis and related skin indications.
Profile data last refreshed 16m ago · AI intelligence enriched 2mo ago
Open Jobs
11-4 this month
Stable — net -4 jobs in 30d
3 added, 7 removed. Backfill posture.
Should You Work at Oruka Therapeutics?
AI assessmentOruka is a solid mid-stage biotech bet for professionals seeking exposure to dermatology biologics and upside equity participation, but requires tolerance for clinical-stage risk and a 3–5 year horizon before potential commercialization.
Why Work Here
- Opportunity to work on a focused, specialized pipeline with two distinct programs (ORKA-001 and ORKA-002) in active clinical development across Phase 1 and Phase 2 trials.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ORKA-001
Healthy VolunteersClinical Trials (1)
NCT06698939ORKA-001 in Healthy Volunteers
Phase 1Help build intelligence for Oruka Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.